Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07582185
Starting soon Phase 4

Tdose Binding and Tocilizumab

NCT07582185 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Nice
Phase
Phase 4
Started
2026-06-01
Last updated
2026-05-12

Condition(s) studied

Rheumatoid Arthritis

Investigational drug(s) / intervention(s)

Experimental: dose binding armActive Comparator: traditionnal arm: Weight-based dosing

Experimental: dose binding arm: TOCILIZUMAB administered at standardized, fixed-interval doses versus weight-based dosing

Active Comparator: traditionnal arm: Weight-based dosing: standart administration; weight-based dosing

Study summary

The investigators aim to evaluate the non-inferiority of administering tocilizumab at a fixed dose versus a weight-based dose in patients with rheumatoid arthritis in remission or with low clinical activity, after 3 months of treatment, as part of a two-center randomized trial.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of rheumatoid arthritis according to ACR/EULAR criteria * Rheumatoid Arthritis in low activity or remission according to DAS28 * Patient to receive a TOCILIZUMAB infusion 8mg/kg * Patient with failure of treatment with cDMARDs or bDMARDs * Concomitant treatment(s) for rheumatism allowed: stable doses for at least 3 months of cDMARDs, NSAIDs, analgesics, or corticosteroid therapy (\< 10 mg/day of prednisone equivalent) Exclusion Criteria: * Active neoplasia * Treatment with TOCILIZUMAB for an indication other than rheumatoid arthritis * Treatment with TOCILIZUMAB at a dosage other than 8 mg/kg * Diverticulitis or history of digestive perforation

Primary outcome measure(s)

  • disease activity — month 3
    DAS28 (0 to 28)

Trial sites (1)

FacilityCityRegionStatus
CHU de Nice Nice France

More Centre Hospitalier Universitaire de Nice trials in France

AI-enhanced Imaging Analysis to Predict Post-EVAR Starting soon
Robotic Emergency General Surgery Program Starting soon
Comparison of Arterial and Capillary Blood Gas Analyses in Patients With Respiratory Distress Due to COPD or APE Recruiting
Videographic Feedback and Walk Rehabilitation in Post-Cerebrovascular Accident Recruiting
Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance. Recruiting

Other trials for the same condition

Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. Recruiting
Prospective Study for the Evaluation of the Cementless Anatomic Femoral Stem Minimax -Launay Active, not recruiting
Post Market Clinical Follow-Up KeriFlex® Recruiting
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07582185 on ClinicalTrials.gov ↗ ← All trials in France